Author:
El Maguid Hala Abd,Heiba Ahmed,El Sayed Enass,El-Hariri Hazem,Tolba Haythem,Abdel Ghaffar Muhammad
Abstract
BACKGROUND: According to the most recent Egyptian demographic health census, the estimated Hepatitis C virus (HCV) prevalence in the 15–59 age range was 14.7%. Globally, the incidence of renal impairment in HCV-positive individuals is 40% higher than in HCV-negative patients. HCV-induced renal impairment can range from mild-to-severe, and it frequently complicates the treatment outcome of HCV infection.
AIM: This study aimed to explore the changes in renal function in Egyptian HCV patients treated with a combination of Sofosbuvir (SOF) and Daclatasvir (DCV).
METHODOLOGY: Six hundred and eleven chronic HCV patients treated with SOF-DCV were enrolled. Patients were classified into three groups according to their baseline renal function: unimpaired group (estimated glomerular filtration rate [eGFR] ≥ 90 ml/min/1.73 m2), mildly impaired group (eGFR of ≥60–89 ml/min/1.73 m2), and moderately impaired group (eGFR of ≥30–59 ml/min/1.73 m2). Every month during treatment and at 24 weeks after treatment (sustained virological response 24), the eGFR level was evaluated.
RESULTS: Our findings indicated that the eGFR level was significantly increased (p < 0.001) in all groups during the treatment but subsequent decline (p < 0.001) in all groups was documented after 6 months of treatment. Multivariate analysis identified baseline renal impairment (<90 ml/min/1.73 m2, p < 0.001) and baseline anemia (p < 0.001) as independent risk factors for renal function deterioration at the end of treatment.
CONCLUSION: Clinical physicians should closely monitor renal function in patients treated with SOF-DCV. Furthermore, anemia therapy prior to SOF-DCV treatment should be recommended.
Publisher
Scientific Foundation SPIROSKI
Reference20 articles.
1. Li M, Wang P, Yang C, Jiang W, Wei X, Mu X, et al. A systematic review and meta-analysis: Does hepatitis C virus infection predispose to the development of chronic kidney disease? Oncotarget. 2016;8(6):10692-702. https://doi.org/10.18632/oncotarget.12896 PMid:27793016
2. Barsoum RS. Hepatitis C virus: From entry to renal injury-facts and potentials. Nephrol Dial Transplant. 2007;22(7):1840-8. https://doi.org/10.1093/ndt/gfm205 PMid:17478492
3. Elgharably A, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD. Hepatitis C in Egypt past, present, and future. Int J Gen Med. 2016;10:1-6. https://doi.org/10.2147/IJGM.S119301 PMid:28053553
4. Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: Real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47(3):421-31. https://doi.org/10.1111/apt.14428 PMid:29193226
5. Glead Siences Inc. Highlights of Prescribing Information. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fwww.gilead.com%2F~%2Fmedia%2Ffiles%2Fpdfs%2Fmedicines%2Fliver-disease%2Fsovaldi%2Fsovaldi_pi.pdf&clen=641835&chunk=true